Status:
COMPLETED
Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This study will test if CP-690,550 is safe and effective in rheumatoid arthritis patients taking methotrexate who have an inadequate response to tumor necrosis factor inhibitor treatment.
Eligibility Criteria
Inclusion
- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate who have inadequate response to Tumor Necrosis Factor (TNF) inhibitors.
Exclusion
- Pregnancy, severe acute or chronic medical conditions, including serious infections or clinically significant laboratory abnormalities.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
399 Patients enrolled
Trial Details
Trial ID
NCT00960440
Start Date
October 1 2009
End Date
March 1 2011
Last Update
December 19 2018
Active Locations (92)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Birmingham, Alabama, United States, 35294
2
Pfizer Investigational Site
Los Angeles, California, United States, 90033
3
Pfizer Investigational Site
Los Angeles, California, United States, 90095
4
Pfizer Investigational Site
San Diego, California, United States, 92108